Cosmos Health Regains Compliance with Nasdaq Minimum Bid Price Requirement
Cosmos Health (NASDAQ:COSM) announced on October 16, 2025 that it has regained compliance with Nasdaq Listing Rule 5550(a)(2), the $1.00 minimum bid price requirement. Nasdaq confirmed the company’s closing bid price was at or above $1.00 for 18 consecutive business days from September 22, 2025 to October 15, 2025. As a result, Nasdaq has closed the matter and the Company is now in compliance with the listing rule. The company said this compliance was achieved organically and attributed to execution of strategic initiatives and strengthening fundamentals, and reiterated focus on shareholder value and its digital asset strategy.
Cosmos Health (NASDAQ:COSM) ha annunciato il 16 ottobre 2025 di aver riacquisito la conformità con la Nasdaq Listing Rule 5550(a)(2), il requisito del prezzo minimo di offerta di 1,00 USD. Nasdaq ha confermato che il prezzo di chiusura dell’offerta era pari o superiore a 1,00 USD per 18 giorni lavorativi consecutivi dal 22 settembre 2025 al 15 ottobre 2025. Di conseguenza, Nasdaq ha chiuso la questione e l’Azienda è ora in conformità con la regola di quotazione. L’azienda ha detto che questa conformità è stata raggiunta organicamente e ha attribuito ciò all’esecuzione di iniziative strategiche e al rafforzamento dei fondamentali, ribadendo l’attenzione al valore per gli azionisti e alla sua strategia di asset digitali.
Cosmos Health (NASDAQ:COSM) anunció el 16 de octubre de 2025 que ha vuelto a cumplir con la Nasdaq Listing Rule 5550(a)(2), el requisito de precio mínimo de oferta de 1,00 USD. Nasdaq confirmó que el precio de oferta de cierre estuvo en o por encima de 1,00 USD durante 18 días hábiles consecutivos desde el 22 de septiembre de 2025 hasta el 15 de octubre de 2025. Como resultado, Nasdaq ha cerrado el asunto y la Compañía ahora cumple con la regla de listado. La empresa indicó que este cumplimiento se logró de forma orgánica y atribuyó ello a la ejecución de iniciativas estratégicas y al fortalecimiento de sus fundamentos, y reiteró su enfoque en el valor para los accionistas y su estrategia de activos digitales.
Cosmos Health (NASDAQ:COSM)는 2025년 10월 16일 나스닥 상장 규정 5550(a)(2) 준수를 재확인했다고 발표했습니다. 1.00달러의 최소 매수가 요건. 나스닥은 회사의 종가 매수가 1.00달러 이상인 상태가 18거래일 연속임을 2025년 9월 22일부터 2025년 10월 15일까지 확인했습니다. 그 결과 나스닥은 이 문제를 종결했고 회사는 이제 상장 규정을 준수합니다. 회사는 이 준수가 자발적으로 달성되었으며 전략적 이니셔티브의 실행과 기초 체력 강화를 통해 달성되었고, 주주 가치 및 디지털 자산 전략에 대한 집중을 재확인했다고 밝혔습니다.
Cosmos Health (NASDAQ:COSM) a annoncé le 16 octobre 2025 avoir retrouvé sa conformité avec la Nasdaq Listing Rule 5550(a)(2), l’exigence du prix d’offre minimum de 1,00 USD. Nasdaq a confirmé que le prix d’offre de clôture était à ou au-dessus de 1,00 USD pendant 18 jours ouvrables consécutifs du 22 septembre 2025 au 15 octobre 2025. En conséquence, Nasdaq a fermé l’affaire et la société est désormais conforme à la règle de cotation. La société a déclaré que cette conformité a été obtenue de manière organique et l’a attribuée à l’exécution d’initiatives stratégiques et au renforcement des fondamentaux, et a réaffirmé son focus sur la valeur pour les actionnaires et sa stratégie d’actifs numériques.
Cosmos Health (NASDAQ:COSM) gab am 16. Oktober 2025 bekannt, dass es die Einhaltung der Nasdaq Listing Rule 5550(a)(2) wiederhergestellt hat, die Mindestgebotspreis von 1,00 USD erfordert. Nasdaq bestätigte, dass der Schlusskurs des Gebots bei oder über 1,00 USD lag bzw. an 18 aufeinanderfolgenden Handelstagen vom 22. September 2025 bis zum 15. Oktober 2025. In der Folge hat Nasdaq die Angelegenheit beendet und das Unternehmen erfüllt nun die Listing-Regel. Das Unternehmen gab an, dass diese Compliance organisch erreicht wurde und auf die Umsetzung strategischer Initiativen und die Stärkung der Fundamentals zurückzuführen sei, und bekräftigte den Fokus auf den Aktionärswert und seine Digital-Asset-Strategie.
Cosmos Health (NASDAQ:COSM) أعلن في 16 أكتوبر 2025 أنه استعاد الامتثال لقائمة ناسداك Rule 5550(a)(2)، متطلب سعر العرض الأدنى البالغ 1.00 دولار. أكدت ناسداك أن سعر عرض الإغلاق كان عند أو فوق 1.00 دولار لمدة 18 يوماً عملياً متتالياً من 22 سبتمبر 2025 حتى 15 أكتوبر 2025. ونتيجة لذلك، أغلقت ناسداك المسألة والآن الشركة في الامتثال لقواعد الإدراج. قالت الشركة إن هذا الامتثال تحقق بشكل عضوي ونسبته إلى تنفيذ مبادرات استراتيجية وتقوية الأساسيات، وأعادت التأكيد على التركيز على قيمة المساهمين واستراتيجيتها للأصول الرقمية.
Cosmos Health (NASDAQ:COSM) 于 2025 年 10 月 16 日宣布已重新符合纳斯达克上市规则 5550(a)(2) 的规定，即1.00 美元的最低竞价价格要 求。纳斯达克确认该公司自 2025 年 9 月 22 日至 2025 年 10 月 15 日的18个连续交易日的收盘竞价在 1.00 美元及以上。结果，纳斯达克已结束此事，该公司现已符合该上市规则。公司表示这一合规性是自发实现的，归因于执行战略举措和强化基本面，并重申将专注于股东价值及其数字资产策略。
- Regained Nasdaq compliance after 18 consecutive business days (Sep 22–Oct 15, 2025)
- Nasdaq has closed the matter, restoring normal listing status
- None.
CHICAGO, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced that on October 15, 2025, it received written notice (the ”Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) confirming that the Company has regained compliance with Nasdaq Listing Rule 5550(a)(2), which requires a minimum bid price of
In the Notice, Nasdaq stated that for the last 18 consecutive business days, from September 22, 2025, to October 15, 2025, the closing bid price of the Company’s common stock has been at or above
Greg Siokas, CEO of Cosmos Health, stated: “We are very pleased to have regained compliance with Nasdaq’s minimum bid price requirement. Importantly, this was achieved organically, reflecting the continued execution of our strategic initiatives and the strengthening of our fundamentals. We remain focused on creating enduring value for our shareholders, guided by our commitment to innovation, operational excellence, and diversification, including the ongoing implementation of our digital asset strategy.”
About Cosmos Health Inc.
Cosmos Health Inc. (Nasdaq:COSM), incorporated in 2009 in Nevada, is a diversified, vertically integrated global healthcare group. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life®, Mediterranation®, bio-bebe®, C-Sept® and C-Scrub®. Through its subsidiary Cana Laboratories S.A., licensed under European Good Manufacturing Practices (GMP) and certified by the European Medicines Agency (EMA), it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. Cosmos Health also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and OTC medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the UK. Furthermore, the Company has established R&D partnerships targeting major health disorders such as obesity, diabetes, and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&D of novel patented nutraceuticals, specialized root extracts, proprietary complex generics, and innovative OTC products. Cosmos Health has also entered the telehealth space through the acquisition of ZipDoctor, Inc., based in Texas, USA. With a global distribution platform, the Company is currently expanding throughout Europe, Asia, and North America, and has offices and distribution centers in Thessaloniki and Athens, Greece, and in Harlow, UK. More information is available at www.cosmoshealthinc.com, www.skypremiumlife.com, www.cana.gr, www.zipdoctor.co, www.cloudscreen.gr, as well as LinkedIn and X.
Forward-Looking Statements
With the exception of the historical information contained in this news release, the matters described herein may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Words such as “believes,” “expects,” “anticipates,” “intends,” “projects,” “estimates,” “plans,” and similar expressions, or future or conditional verbs such as “will,” “should,” “would,” “may,” and “could,” generally identify forward-looking statements, although not all forward-looking statements contain these words. These statements involve risks and uncertainties that may individually or materially affect the matters discussed herein for a variety of reasons outside the Company’s control, including, but not limited to: the Company’s ability to raise sufficient financing to implement its business plan; the effectiveness of its digital asset strategies, including accumulation and yield-generating activities; the impact of the war in Ukraine on the Company’s business, operations, and the economy in general; and the Company’s ability to successfully develop and commercialize its proprietary products and technologies. Readers are cautioned not to place undue reliance on these forward-looking statements, as actual results could differ materially from those anticipated. Readers are encouraged to review the risk factors set forth in the Company’s filings with the SEC, which are available at the SEC’s website (www.sec.gov). The Company disclaims any obligation to update or revise forward-looking statements, whether as a result of new information, future events, or otherwise
Investor Relations Contact:
BDG Communications
cosm@bdgcommunications.com
FAQ
What did Cosmos Health (COSM) announce on October 16, 2025 about Nasdaq compliance?
Which dates confirm COSM met Nasdaq's minimum bid price requirement?
What is the immediate effect for COSM after regaining Nasdaq compliance?
Does the Cosmos Health announcement say how compliance was achieved for COSM?
Will Cosmos Health (COSM) face further Nasdaq review after regaining compliance?
How does the Nasdaq notice affect COSM shareholders in the short term?
